SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IGA NEPHROPATHY (IGAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL

Introduction:

SPAR is a nonimmunosuppressive, dual endothelin and angiotensin receptor antagonist (DEARA) approved in the US and EU for the treatment of adults with IgAN. SPARTAN (NCT04663204) is an open-label, single-arm, multicenter, exploratory trial investigating the safety, efficacy, and mechanistic action of SPAR as first-line therapy in patients newly diagnosed with IgAN. We report interim findings.
 

Methods:

Twelve patients ≥18 y old with biopsy-proven IgAN, proteinuria of ≥0.5 g/d, eGFR of ≥30 mL/min/1.73 m2, and no prior treatment with ACEis/ARBs (≤12 mo) were enrolled. SPAR is given for 110 wk with 4-wk safety follow-up. In a prespecified 24-wk interim analysis, proteinuria, GFR, BP, body weight, total body water (bioimpedance), and safety were assessed.
 

Results:

Mean age at enrollment was 35.8 (SD 12.2) y (5 female), with median (IQR) proteinuria of 1.7 (0.6-3.3) g/d and mean eGFR of 70.2 (SD 25.0) mL/min/1.73 m2 at baseline (BL). Proteinuria reductions were rapid (−61.9% [±SE −66.9 to −56.1] from BL to wk 4) and sustained over 24 wk (Figure); 58% of patients achieved complete proteinuria remission (<0.3 g/d) at any time during the first 24 wk of treatment. After an initial decrease from BL (125/78 mm Hg), BP remained stable during follow-up; eGFR, total body water, and body weight were generally stable (Table). The most frequent AE was dizziness (50% of patients); 1 patient discontinued due to hypotension.
 

Conclusions:

In patients newly diagnosed with IgAN, interim findings show that SPAR as first-line treatment was generally well tolerated and reduced proteinuria ≈70% over 24 wk.

This abstract was also submitted for the American Society of Nephrology Kidney Week 2024 congress.

I have potential conflict of interest to disclose.
Employee and shareholder of Travere Therapeutics, Inc

I did not use generative AI and AI-assisted technologies in the writing process.